MedTrace Logo

The Impact of Magnesium on Exercise Tolerance, Quality of Life and Clinical Outcomes in Chronic Heart Failure Patients

NCT03840226 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2023-12-12

No results posted yet for this study

Summary

Magnesium supplementation could improve cardiac performance. Patients with chronic heart failure (CHF) are magnesium deficient and we hypothesized that 1 year supplementation of oral magnesium comparted to placebo will improve exercise duration time and quality of life.

Conditions

Interventions

DRUG

Placebo Oral Tablet

Placebo tablets

DRUG

Magnesium Oxide

Magnesium tablets

Sponsors & Collaborators

  • Naveh Pharma (1996) Ltd.

    collaborator UNKNOWN

  • Sheba Medical Center

    lead OTHER_GOV

Principal Investigators

  • Michael Shechter, MD · Sheba Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-25
Primary Completion
2026-01-01
Completion
2026-03-01

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03840226 on ClinicalTrials.gov